RenovoRx, Inc. (RNXT)

In August 2025, RenovoRx reported its second-quarter financial results, with RenovoCath revenue exceeding expectations and EPS landing better than expected. The DMC recommended continuing the Phase III TIGeR-PaC trial after reviewing the second pre-planned interim analysis. In the third quarter of 2025, RenovoRx reported revenue that missed forecasts, while EPS met expectations. In December 2025, RenovoRx received a Nasdaq notice for bid price noncompliance, but there were also reports of insider buying. In January 2026, RenovoRx announced promising new clinical data to be presented at the ASCO GI 2026 symposium, and the stock price experienced a decline.

Information specifically detailing demand seasonality for RenovoRx, Inc.'s products and services is not readily available. While there is increasing demand for its RenovoCath device, leading to increased production and repeat purchase orders, this does not indicate a seasonal trend.

RenovoRx, Inc. is a clinical-stage medical technology and biopharmaceutical company focused on developing targeted oncology therapies. Their core mission is to improve cancer patient outcomes through targeted delivery of diagnostic and therapeutic agents. The company's major product is RenovoCath™, an FDA-cleared intra-arterial catheter system designed for precise fluid delivery. RenovoRx is also evaluating intra-arterial gemcitabine (IAG) delivered via RenovoCath, which has received Orphan Drug Designation from the FDA for pancreatic and bile duct cancer and is currently in Phase III clinical trials.

RenovoRx, Inc. is headquartered in Mountain View, California, and has been expanding its commercial reach within the U.S. As of August 2025, the company had expanded its commercial footprint to 13 cancer centers approved to purchase its RenovoCath device, an increase from five centers in the first quarter of 2025. Four of these centers were actively using the device in patients and had placed repeat orders. The company anticipates that many of the 18 cancer centers participating in its TIGeR-PaC clinical trial could become potential customers after trial enrollment is completed.

RenovoRx's brand reputation, based on analyst sentiment, ranges from "Hold" to "Strong Buy." MarketBeat indicates a consensus rating of "Hold," while TipRanks shows an "Analyst Consensus" of "Strong Buy." Positive events impacting the company's reputation include the expansion of its commercial footprint, the positive recommendation from the DMC for the TIGeR-PaC trial, commercial revenue growth for RenovoCath, and the acceptance of clinical data abstracts for presentation at major conferences.

RenovoRx, Inc. has a mixed ownership structure, including institutional, retail, and individual investors. Institutional investors hold approximately 11.87% to 20.68% of the company's stock, with major holders including AIGH Capital Management LLC and Vanguard Group Inc. Insiders own approximately 3.46% to 9.13% of the stock. The general public and individual investors hold a significant portion, around 75.85% of the stock.